Note 18 - Segment Information (Tables)

3 Months Ended

Mar. 31, 2026

Notes Tables

Segment Reporting [Table Text Block]

	As of March 31, 2026						As of December 31, 2025
	Biopharma		CDMO		Consolidated		Biopharma		CDMO		Consolidated
Cash and cash equivalents	$	6,937	$	278	$	7,215	$	12,277	$	368	$	12,645
Prepaid expenses and other current assets		233		454		687		156		190		346
Property and equipment, net		30		12,614		12,644		34		12,607		12,641
Deferred offering costs		555		—		555		136		—		136
Licensed technology, net		2,993		—		2,993		2,243		—		2,243
Operating lease right-of-use assets, net		—		10,086		10,086		—		—		—
Goodwill		—		3,457		3,457		—		3,457		3,457
Restricted cash		368		—		368		—		—		—
Other assets		126		84		210		124		—		124
Total consolidated assets of continuing operations	$	11,242	$	26,973	$	38,215	$	14,970	$	16,622	$	31,592

		Three Months Ended March 31, 2026									Three Months Ended March 31, 2025
	Biopharma			CDMO			Consolidated			Biopharma			CDMO		Consolidated
Operating Expenses
Research and development	$	857		$	997		$	1,854		$	335		$	—	$	335
Selling, general and administrative		2,054			1,726			3,780			1,042			—		1,042
Total operating expenses		2,911			2,723			5,634			1,377			—		1,377
Other expense (income)
Change in fair value of derivative liability		33			—			33			—			—		—
Interest income		24			—			24			4			—		4
Interest expense		(648	)		—			(648	)		—			—		—
Net other (expense) income		(591	)		—			(591	)		4			—		4
Net loss from operations before discontinued operations	$	(3,502	)	$	(2,723	)	$	(6,225	)	$	(1,373	)	$	—	$	(1,373	)